Objective: Orlistat and sibutramine are widely prescribed antiobesity agents that are approved for 2 years of continuous use. Previous 1-4-year randomized, placebo-controlled trials of these drugs have reported average weight losses of o5 kg, significant adverse effects and attrition rates of up to 60%. The objective of this study was to determine the long-term persistence with orlistat and sibutramine therapy outside a clinical trial setting. Design, setting and patients: Population-based administrative data from British Columbia, Canada, were used to create an inception cohort of orlistat and sibutramine users and determine the 2-year persistence with therapy. Main outcome measure: Persistence with therapy at 2 years. Drug discontinuation was defined as the failure to refill a prescription within 120 days. Patients discontinuing therapy were censored at the 60-day mark. Results: Nearly 17 000 users of orlistat and 3500 users of sibutramine were identified. For both orlistat and sibutramine, 1-year persistence rates were o10% and 2-year persistence rates were 2%. Conclusion: This population-based, retrospective cohort analysis demonstrated very poor long-term persistence rates with orlistat and sibutramine and discontinuation rates that were much higher than those reported in clinical trials. Keywords: orlistat; sibutramine; adherence; population health; endocrinology; metabolism Antiobesity drugs are commonly used and generate hundreds of million dollars in annual sales.
for up to 2 years of continuous use, produce 1-4-year average placebo-subtracted weight losses of o5 kg, are costly, and can cause significant adverse events. 3 Orlistat frequently causes gastrointestinal distress and sibutramine may raise blood pressure and heart rate. To date, no cardiovascular morbidity or mortality outcome data exist for either agent, although a large 5-year randomized trial involving sibutramine is currently underway. 4 Orlistat reduced diabetes incidence in a recent 4-year trial 5 ; however, the internal validity of this study was limited by an attrition rate of 57%. One-year weight loss trials of orlistat and sibutramine have reported similarly high attrition rates, averaging 33 and 48%, respectively. 3 The high attrition rates reported in randomized controlled trials (RCTs) of these drugs raises the concern that persistence rates outside the RCT setting are even poorer. Recent data suggest that the long-term persistence with cardiovascular drug therapy in a non-RCT setting is suboptimal, even with agents that have been proven to lower cardiovascular morbidity and mortality. For example, over a 2-year period, only 25-40% of patients prescribed statin therapy persisted with treatment in a large, population-based elderly cohort. 6 Similarly, only 40-53% of patients receiving antihypertensive drugs persisted with therapy after 4.5 years. 7 To our knowledge, no study has examined persistence rates with orlistat and sibutramine in a population-based setting outside a RCT. The major objective of this study was to determine the long-term persistence rates with orlistat and sibutramine using administrative data from the province of British Columbia (BC), Canada.
Methods

Data sources
The approximately four million residents of BC are serviced by a publicly funded health-care system, where eligible individuals may freely access hospital and physician services. Health-care utilization is captured in comprehensive administrative databases that are anonymously linked using patient-specific identifiers. PharmaNet and the British Columbia Linked Health Database (BCLHD) were the two main data sources for this study and have been used in numerous prior peer-reviewed publications. 8 PharmaNet is an electronic database that records all prescriptions dispensed in B.C. pharmacies from September 1995 onwards.
Although PharmaNet has not been directly validated, a recent study of a very similar database in Ontario (Canada), known as the Ontario Drug Benefits (ODB) program, reported an overall discrepancy rate of o1% when comparing electronically submitted prescription claims to the original written prescription. 9 The BCLHD is a collection of individual data sets for the entire population of BC, available from 1985 onwards. Hospitalization and mortality data were obtained from this database.
Cohort assembly A priori, we decided to analyze persistence rates with orlistat and sibutramine in separate cohorts. Including these drugs in the same analysis would have resulted in 'double counting' of those patients trying both drugs during the follow-up period. PharmaNet data were used to assemble an inception cohort of orlistat and sibutramine users from January 2001 to December 2003. The entry date into the cohort was the date of initial prescription and is hereafter referred to as the index date. New users were defined as patients who had not received the drug in question in the year before the index date. Patients were followed until they discontinued therapy, died or reached the end of the followup period.
Baseline characteristics
The baseline cardiovascular comorbidities of orlistat-and sibutramine-treated patients were defined using Pharmanet drug prescriptions (in the year before the index date) and/or hospitalization records (up to 5 years before the index date). Specific diagnostic codes and drugs used for each condition are available from the corresponding author. Socioeconomic status quintile was defined using neighborhood income as a proxy measure. 10 
Statistical analysis
Kaplan-Meier plots were used to examine persistence with therapy. The dependent variable was time to discontinuation of therapy. Discontinuation was defined as the failure to refill a prescription within 120 days of the date of the last prescription. A 120-day window period was chosen because it was considered a conservative definition of adherence and has been previously used in similar studies assessing adherence with other agents. 6 Because patients who discontinued therapy could have done so at any point during this window period, they were censored at the midpoint of this 120-day period. Censoring also occurred if patients died or reached the end of follow-up.
Results
Primary analysis
There were 16 968 users of orlistat and 3466 users of sibutramine identified (Table 1 ). Orlistat and sibutramine were most commonly prescribed to middle-aged women with no previous history of cardiovascular disease. The mean follow-up time was 116 days for orlistat and 135 days for sibutramine. Six-month, 1 year and 2-year persistence rates with orlistat were 18, 6 and 2%, respectively. Corresponding rates for sibutramine were 26, 8 and 2%, respectively ( Figure 1 ). Many patients discontinued therapy after the initial prescription ( Figure 1 ).
Discussion
In this retrospective, longitudinal population-based cohort analysis, only 2% of patients persisted with orlistat or sibturamine therapy at 2 years. Discontinuation rates were much higher than those observed in RCTs and also much greater than those of other cardiovascular drugs prescribed to similar patient populations. 6, 7, 11 Several limitations to this study should be noted. First, data on anthropometric indices such as waist circumference, weight and body mass index (BMI) were not available. Thus, we assumed that antiobesity drugs were being prescribed to overweight and obese individuals only, but cannot verify this assumption. Previous data suggest that 13% of patients taking weight loss drugs have BMI levels under 27 kg/m 2 and, in these cases, drugs were obtained by physician prescription only 25% of the time. 12 Therefore, it is likely that the vast majority of patients in this study were prescribed antiobesity therapy appropriately. Second, only patients who filled at Long-term persistence with orlistat and sibutramine R Padwal et al least one prescription for an antiobesity drug were included and patients given samples by their physicians were not captured. This likely overestimated persistence rates, as individuals receiving samples and not subsequently filling prescriptions would have had very short durations of therapy. Patients receiving a sample and then filling a prescription would have been identified and included. Third, this study involved the use of retrospective administrative databases not originally designed to examine persistence rates. However, as discussed above, the validation studies that do exist for these and similar databases suggest that that data are accurately coded. Prescription refill rates in administrative databases are generally felt to accurately reflect drug adherence in closed pharmacy systems such as provincial databases, 13 although medication refills are not necessarily equivalent to medication ingestion. We did not have information on the underlying reason(s) for drug discontinuation although, given prior evidence, 3 modest efficacy, adverse effects and expense probably were contributing factors. Current guidelines recommending discontinuation of orlistat therapy after 8-12 weeks if 4.4-5 kg of weight loss has not been achieved [14] [15] [16] may have promoted drug discontinuation. Supportive care and frequency of follow-up may also have been lower than that provided in clinical trials and this may have been an additional factor leading to drug discontinuation. It is notable that 1 month of orlistat or sibutramine therapy costs approximately US$120-$140, which is not an inconsequential expense for a condition that disproportionately affects those of low socioeconomic status. Neither drug is paid for by the provincial drug plan in BC. In contrast, drug coverage is commonly provided in Canada for other cardiovascular drugs such as statins, antihypertensives and metformin, which may partly explain the higher rates of persistence for these agents demonstrated in other studies. 6, 7 An alternate explanation for poor persistence is that the high discontinuation rates reflected substantial druginduced weight loss, in which continued therapy was no longer required. In placebo-controlled 1-year randomized trials enrolling patient populations highly selected to maximize efficacy and minimize toxicity, orlistat reduced weight by 2.9% (95% confidence interval (CI): 2.3-3.4%) and sibutramine by 4.6% (95% CI: 3.8-5.4%).
3 It is extremely unlikely that the weight-reducing effects of orlistat or sibutramine were substantially greater on a population-wide level outside a clinical trial setting. Furthermore, a 3-month observational study in 789 Swedish patients from a primary and secondary care setting found that orlistat was associated with 2-3% weight reductions, similar to the weight reductions observed in clinical trials. 17 Previous studies documenting poor persistence rates with therapies such as statins and antihypertensive agents have been followed by efforts to increase adherence. 13, 18 In contrast to the well-documented cardiovascular benefits of statins and antihypertensive drugs, 19, 20 no cardiovascular outcome data exist for either orlistat or sibutramine. In fact, concerns have been raised regarding the potential cardiotoxicity of sibutramine, 21 but these data are not definitive, 22, 23 and this agent is currently being evaluated in a 9000-patient, 5-year cardiovascular outcome study. 4 In the absence of cardiovascular end point data, the use of orlistat and sibutramine has been justified based on the modest weight losses and improvements in cardiovascular risk factors observed in randomized trials. Modeling techniques utilizing extrapolations of these data have predicted reductions in cardiovascular disease and favorable pharmacoeconomic benefits with orlistat and sibutramine therapy. 24, 25 However, such analyses have not probably accounted for the extremely poor persistence rates demonstrated in this study. In summary, the long-term persistence with orlistat and sibutramine therapy in this population-based observational cohort was exceedingly poor and much lower than corresponding persistence rates in RCTs. Further research is required to determine the underlying reasons for such poor persistence rates with these commonly prescribed drugs. Long-term persistence with orlistat and sibutramine R Padwal et al source and was approved by the ethics panel at the University of Alberta.
